首页> 美国卫生研究院文献>Canadian Journal of Kidney Health and Disease >Total Kidney Volume as a Biomarker of Disease Progression in Autosomal Dominant Polycystic Kidney Disease
【2h】

Total Kidney Volume as a Biomarker of Disease Progression in Autosomal Dominant Polycystic Kidney Disease

机译:总肾脏体积作为常染色体显性多囊肾疾病进展的生物标志物

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Purpose of review:Autosomal dominant polycystic kidney disease (ADPKD) is an inherited disorder characterized by the formation of kidney cysts and kidney enlargement, which progresses to kidney failure by the fifth to seventh decade of life in a majority of patients. Disease progression is evaluated primarily through serum creatinine and estimated glomerular filtration rate (eGFR) measurements; however, it is known that serum creatinine and eGFR values typically do not change until the fourth or fifth decade of life. Until recently, therapy only existed to target complications of ADPKD. As therapeutic agents continue to be investigated for use in ADPKD, a suitable biomarker of disease progression in place of serum creatinine is needed.
机译:综述目的:常染色体显性遗传性多囊肾病(ADPKD)是一种遗传性疾病,其特征是肾囊肿形成和肾脏肿大,在大多数患者中,该病在生命的第五个到第七个十年发展为肾功能衰竭。主要通过血清肌酐和估计的肾小球滤过率(eGFR)测量来评估疾病的进展;但是,众所周知,血清肌酐和eGFR值通常在生命的第四个或第五个十年之前不会改变。直到最近,仅存在针对ADPKD并发症的疗法。随着继续研究将治疗剂用于ADPKD中,需要合适的疾病进展的生物标志物代替血清肌酐。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号